CTRI/2023/07/055047
Not yet recruiting
Phase 2
A Phase 2 randomized study to assess the radioprotective effect of oral chlorophyllin in acute toxicity reduction for Head Neck cancer patients receiving radiation / chemoradiation. - NI
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Health Condition 1: C139- Malignant neoplasm of hypopharynx,unspecifiedHealth Condition 2: C119- Malignant neoplasm of nasopharynx,unspecifiedHealth Condition 3: C109- Malignant neoplasm of oropharynx,unspecifiedHealth Condition 4: C148- Malignant neoplasm of overlappingsites of lip, oral cavity and pharynx
- Sponsor
- Tata Memorial Hospital
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •A.Patients with histologically proven Squamous Cell Carcinoma of the Oropharynx, Nasopharynx, Oral Cavity, Larynx and Hypopharynx planned for curative intent RT (either definitive or post\-op).
- •B. Patients who have not received any other cancer directed treatment in the past.
- •C. Patients willing to sign the informed consent form.
Exclusion Criteria
- •A. Patients who have received NACT before local therapy
- •B. Patients \> 70 years of age
- •C. Patients with severe comorbidities ( \> 2 ACE 27 score)
- •D. Patients with baseline feeding tube
- •E. Synchronous / Metachronous Primaries
- •F. Non\-Squamous Histology
- •G. Patients receiving non\-platinum concurrent chemotherapy
- •H. Treated with palliative intent
- •I. Not reliable for follow up
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A randomised Phase II/III trial to study radiotherapy dose escalation in patients with oesophageal cancer treated with definitive chemo-radiation with an embedded Phase II trial for patients with a poor early response using positron emission tomography (PET)on operable oesophageal cancer patientsMedDRA version: 19.1Level: LLTClassification code 10030151Term: Oesophageal cancerSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2015-001740-11-GBVelindre NHS Trust
Active, not recruiting
Not Applicable
The SCOPE 2 Trial: Study of chemoradiotherapy in oesophageal cancer including PET response and dose escalatioISRCTN97125464Velindre NHS Trust439
Recruiting
Phase 2
Phase II non-randomized study on proton radiotherapy of thymic malignanciescancerThymoma10027655NL-OMON51962Swedish Lung Cancer Study Group10
Recruiting
Phase 2
preceding RFA to Atezo+Bev for HCC patientshepatocellular carcinomaJPRN-jRCT1041200075Yamashita Tatsuya66
Active, not recruiting
Phase 1
A study to investigate the effect of addition of metformin to standard treatment in patients with inoperable stage III non-small cell lung cancer.EUCTR2017-004877-15-BEAntwerp University Hospital, Department Thoracic Oncology104